Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity

• Published in: Pathogens (Basel) Vol. 10; no. 1; p. 5
• Main Authors: Karmakar, Deepmala, Lahiri, Basudev, Ranjan, Piyush, Chatterjee, Jyotirmoy, Lahiri, Pooja, Sengupta, Sanghamitra
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 23.12.2020; MDPI AG
• Subjects: clinical-immunological features; COVID-19; disease severity; host immunity; Review; SARS-CoV-2; COVID-19; clinical-immunological features; SARS-CoV-2; disease severity; host immunity
• ISSN: 2076-0817; 2076-0817
• DOI: 10.3390/pathogens10010005

SARS-CoV-2, a novel coronavirus, was first identified in Wuhan, China in December 2019. The rapid spread of the virus worldwide prompted the World Health Organization (WHO) to declare COVID-19 a pandemic in March 2020. COVID-19 discontinuing's a global health crisis. Approximately 80% of the patients infected with SARS-CoV-2 display undetectable to mild inflammation confined in the upper respiratory tract. In remaining patients, the disease turns into a severe form affecting almost all major organs predominantly due to an imbalance of innate and adaptive arms of host immunity. The purpose of the present review is to narrate the virus's invasion through the system and the host's reaction. A thorough discussion on disease severity is also presented regarding the behavior of the host's immune system, which gives rise to the cytokine storm particularly in elderly patients and those with comorbidities. A multifaceted yet concise description of molecular aspects of disease progression and its repercussion on biochemical and immunological features in infected patients is tabulated. The summary of pathological, clinical, immunological, and molecular accounts discussed in this review is of theranostic importance to clinicians for early diagnosis of COVID-19 and its management.